• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

EyePoint Pharmaceuticals raises $29m to fund Dexycu product launch

October 2, 2018 By Sarah Faulkner

Eyepoint Pharmaceuticals updated logoEyePoint Pharmaceuticals (NSDQ:EYPT) said today that it received $28.9 million in proceeds from the exercise of warrants by EW Healthcare Partners, Rosalind Advisors and another accredited investor.

Last month, the Watertown, Mass.-based company won transitional pass-through status and reimbursement of its dexamethasone intraocular suspension, Dexycu, from the Centers for Medicare and Medicaid Services.

The FDA-approved product is designed to treat inflammation following cataract surgery using a single, intraocular dose of long-acting dexamethasone.

“We are pleased to receive the continued support of  EW Healthcare Partners, Rosalind Advisors and our other investors, for our innovative pipeline of ocular disease products,” president & CEO Nancy Lurker said in prepared remarks. “The additional capital will fund our ongoing commercialization initiatives for the planned product launches of Dexycu and, if approved, Yutiq, in the first half of 2019, as well as general corporate purposes to support our transition into a commercial-stage organization.”

The FDA is slated to make a decision about the new drug application for EyePoint’s Yutiq product by Nov. 5. The company’s lead product candidate is designed as a three-year treatment for non-infectious posterior segment uveitis.

EYPT shares were trading at $3.48 apiece in mid-morning activity today, down -2.8%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: eyepointpharmaceuticals

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS